ArticleAntimicrobial agents and chemotherapy2020
Oral Fosfomycin Efficacy with Variable Urinary Exposures following Single and Multiple Doses against
Article in Antimicrobial agents and chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 16 citations in OpenAlex.
- Nemonoxacin pharmacokinetics/pharmacodynamics againstAntimicrobial agents and chemotherapy · 2026Article
- A nutrient bottleneck controls antibiotic efficacy in structured bacterial populations.Nature communications · 2026Article
- Heteroresistance associated with the production of fosfomycin-resistant inner colonies during disk diffusion testing among a geographically diverse collection ofJAC-antimicrobial resistance · 2025Article
- Epidemiology, mechanisms, and clinical impact of bacterial heteroresistance.npj antimicrobials and resistance · 2025Review
- DynamicAntibiotics (Basel, Switzerland) · 2024Review
- Plasma and Urine Pharmacokinetics of Oral Fosfomycin Tromethamine in Dogs.Veterinary sciences · 2023Article
- Activity of fosfomycin and amikacin against fosfomycin-heteroresistantAntimicrobial agents and chemotherapy · 2023Article
- Review
- Review
- Oral Fosfomycin Treatment for Enterococcal Urinary Tract Infections in a DynamicAntimicrobial agents and chemotherapy · 2020Article
- Fosfomycin susceptibility of uropathogens at Charlotte Maxeke Johannesburg Academic Hospital.Southern African journal of infectious diseases · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral fosfomycin trometamol is licensed as a single oral dose for the treatment of uncomplicated urinary tract infections, with activity against multidrug-resistant uropathogens. The impact of interindividual variability in urinary concentrations on antimicrobial efficacy, and any benefit of giving multiple doses, is uncertain. We therefore performed pharmacodynamic profiling of oral fosfomycin, using a dynamic bladder infection
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.